Showing results (691-700 of 708) with videos related to

Sort By:
Pageof 71
JAMA|August 18, 1999
Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial InvestigatorsJ A Staessen, L Thijs, R Fagard, et al.
Journal of Hypertension|February 12, 1998
24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' GroupR Fogari, S Ambrosoli, L Corradi, et al.
Diabetologia|January 31, 2012
Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitusG S Hillis, M Woodward, A Rodgers, et al.
Journal of Internal Medicine|November 29, 2014
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studiesM Böhm, H Schumacher, R E Schmieder, et al.
Clinical Endocrinology|January 12, 2012
Decreased adrenergic tone in acromegaly: evidence from direct recording of muscle sympathetic nerve activityG Seravalle, C Carzaniga, R Attanasio, et al.
Lancet (London, England)|April 5, 1997
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) InvestigatorsJ R Hampton, D J van Veldhuisen, F X Kleber, et al.
Journal of Human Hypertension|August 31, 2007
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to actionG Bakris, M Hill, G Mancia, et al.
Controlled Clinical Trials|July 31, 1998
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) TrialH R Black, W J Elliott, J D Neaton, et al.
Lancet (London, England)|September 4, 2007
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialAnushka Patel, , S MacMahon, et al.
Diabetologia|August 19, 2009
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trialB E de Galan, S Zoungas, J Chalmers, et al.
Pageof 71